PDCD1 and non-small cell lung carcinoma: In brief, this cohort was representative of advanced NSCLC patients with median age of 67 years (range, 31–90) and major proportion of LUAD (77.4%), in which 94.0% of patients received anti-PD-1/PD-L1 monotherapy and the rest underwent anti-PD-1/PD-L1 and anti-CTLA-4 combination therapy.